STAT+: Cue Health rode Covid-19 to an NBA deal and a $3 billion valuation. Now it faces layoffs and a rocky future
It didn’t have the brand recognition of Abbott, or the billions of the medical technology…
Category: STAT+
STAT+: Pharmalittle: Sarepta halts a Duchenne clinical trial over safety; Why the CVS Health whistleblower lawsuit comes at a pivotal moment
And so, another working week will soon draw to a close. Not a moment too…
STAT+: FDA halts study of Sarepta treatment for Duchenne muscular dystrophy due to safety concern
Sarepta Therapeutics said Thursday that it has temporarily stopped a clinical trial of its second-generation…
STAT+: A CVS whistleblower lawsuit comes at a pivotal moment for the FTC’s probe of pharma and PBMs
Three years ago, a former CVS Health executive told a U.S. Senate committee hearing that…
STAT+: A cautionary tale: How one biotech stock trader lost a small fortune, but emerged wiser
Too many of my Twitter interactions with biotech-loving retail investors are unpleasant. If I write…
STAT+: Pharmalittle: Senate bill would allow insulin makers to lock in profits; GSK, Novartis pledge funds for diseases that mostly affect the poor
Rise and shine, everyone, another busy day is on the way. We can tell because…
.jpg)
STAT+: Uniqure’s Huntington’s gene therapy lowers key protein in small trial
A gene therapy for Huntington’s disease made by the Dutch biotech firm Uniqure showed early…
STAT+: Despite fanfare, the FDA’s step toward lowering nicotine levels in cigarettes is a very early one
WASHINGTON — When the Food and Drug Administration said Tuesday it would eventually lower the…
STAT+: With cryptocurrency and NFTs, ‘decentralized science’ seeks to upend drug industry financing
When Alok Tayi’s daughter was born last year, he found himself in a place no…
.jpg)
STAT+: New Senate proposal to lower insulin prices would let drugmakers lock in their current profits
WASHINGTON — A new proposal that senators claim would fix insulin pricing would actually allow…
STAT+: Congress is closer than ever to formally authorizing ARPA-H. But the details aren’t as final as they seem
WASHINGTON — It seemed like the debate over President Biden’s new high-stakes science agency, ARPA-H,…
STAT+: Industry-funded studies on cost-effectiveness often favor pricier drugs, study finds
In response to rising prices for medicines, public and private payers increasingly rely on assessments…
STAT+: Pharmalittle: U.K. inks $1.2 billion deal with Moderna for vaccine center; Top Biocon exec arrested in bribery scandal
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: Startup will target cystic fibrosis with a new twist on gene therapy
Gene therapy developers rely on hollowed-out viruses to shuttle DNA into the body, where it…
STAT+: Senate lawmakers introduce a bill to help the FDA and the U.S. Patent Office coordinate
Amid concerns that patent reviewers disregard competitive effects on prescription drugs, a bipartisan group of…
STAT+: Supreme Court rules in favor of insurance plan that pushed kidney failure patient to Medicare
Patients with kidney failure face a murky future if they have insurance coverage through a…
STAT+: PTC’s Duchenne muscular dystrophy drug achieves study goal, potentially confirming European approval
PTC Therapeutics said Tuesday that its treatment for Duchenne muscular dystrophy slowed the loss of…
STAT+: Pharmalittle: Medicare could have saved billions if it paid what Cuban charges; India’s drug controller accused of taking bribe
Top of the morning to you, and a fine one it is. The sun is…
STAT+: European researchers seek greater stake in drug development in bid to improve access
As the price of new medicines weighs on health payers in Europe, universities are seeking…
STAT+: European Commission investigates Vifor for ‘disparaging’ its only rival in iron deficiency market
The European Commission has opened an investigation into allegations that Vifor Pharma spread misleading information…
STAT+: Smartphone apps promised to help combat the pandemic. How well did they work?
When the pandemic hit, tech giants like Apple and Google as well as upstart technology…
STAT+: Pharmalittle: Merck is eyeing Seagen to beef up its cancer drug portfolio; Lawmakers want GAO to probe PBMs
Good morning, everyone, and welcome to another working week, although today is actually a holiday…
STAT+: Lawmakers ask GAO to probe pharmacy benefit managers over their role in drug pricing
Amid intensifying scrutiny of pharmacy benefit managers, a group of House Republicans is urging the…
STAT+: HCA, Steward abandon hospital deal in another win for FTC
For-profit hospital chains HCA Healthcare and Steward Health Care have terminated their proposed hospital sales,…
STAT+: A longtime investor talks interest rates, biotech, and why luxury cars are a warning sign
This week the central bank hiked interest rates by three quarters of a percentage point,…
STAT+: Pharmalittle: FTC warns pharma and PBMs about rebate schemes; WTO reaches Covid vaccine patent waiver deal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: WTO reaches a deal on Covid vaccine patent waivers, but industry and advocates remain unhappy
After nearly two years of talks, the World Trade Organization reached an agreement to temporarily…
STAT+: FTC puts drugmakers and PBMs on notice that it will crack down on illegal rebate schemes
In a notable move, the Federal Trade Commission put drugmakers and pharmacy benefit managers on…
STAT+: Pharmalittle: CVS whistleblower suit details plans to boost consumer drug costs; Roche reports negative Alzheimer’s trial results
Hello, everyone, and how are you today? Another dank cloudy cover greeted us this morning,…
STAT+: A Roche treatment fails to slow cognitive decline in patients with inherited form of Alzheimer’s disease
Roche reported negative results Thursday from a long-running clinical trial investigating an experimental antibody treatment…
STAT+: Facebook is receiving sensitive medical information from hospital websites
A tracking tool installed on many hospitals’ websites has been collecting patients’ sensitive health information…
STAT+: Verily co-founder lays out vision for how real-world data can transform health care
SAN DIEGO — The real world’s a messy place, but there’s a lot you can…
STAT+: A ‘veritable playground’: CVS whistleblower details how patients were charged higher drug prices
The conversation reflected frustration and disbelief. A woman had called SilverScript, which runs one of…
STAT+: Supreme Court sides with hospitals on Medicare drug pay dispute
WASHINGTON — The Supreme Court on Wednesday sided with hospitals in a legal dispute over…
STAT+: Pharmalittle: FDA panel to review Covid shots for young children; Shionogi to license antibiotic to dozens of poor countries
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
STAT+: FDA oversight of pharma manufacturing facilities plunges during the pandemic
Each year, the Food and Drug Administration tracks its progress inspecting pharmaceutical manufacturing facilities and…
STAT+: Third Rock Ventures plots next chapter after raising $1.1 billion fund
Third Rock Ventures has raised $1.1 billion for its largest-ever fund, the biotech venture capital…
STAT+: Many Blue Cross Blue Shield plans aren’t paying taxes — and instead are swimming in refunds
The Blue Cross Blue Shield system of health insurance companies boasts on its website, “We…
STAT+: In a first-of-its-kind deal, major drugmaker licenses antibiotic production for low-income countries
In a first-of-its-kind arrangement, Shionogi has reached an agreement with the Global Antibiotic Research and…
STAT+: New Jersey hospitals scrap merger after FTC challenge
Two New Jersey hospital systems have called off their proposed merger less than two weeks…
STAT+: Pharmalittle: Lawmakers urge FTC to probe blood thinner prices; EU pressures Covid vaccine makers to renegotiate contracts
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: Amylyx’s case for approval of its ALS drug isn’t ironclad. Here’s why I think it will still happen
The odds that Amylyx Pharmaceuticals wins approval from the Food and Drug Administration for Albrioza,…
STAT+: A widely anticipated ALS drug wouldn’t be cost effective if priced the same as an older rival
Amid growing demand for ALS treatments, a preliminary analysis finds an experimental medicine that may…
STAT+: FDA approved more cancer drugs than EMA, but they may not have always benefited patients
Amid rising pressure to endorse new medicines, U.S. regulators greatly outpaced their European counterpart in…
Eli Lilly wins FDA approval for first-ever treatment for hair loss caused by autoimmunity
The Food and Drug Administration on Monday approved an Eli Lilly drug that is the…
STAT+: Pharmalittle: Canada OKs ALS drug still waiting FDA approval; WTO talks on Covid patent waiver are down to the wire
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Canada approves ALS drug from Amylyx Pharma as U.S. patients await extended review
Amylyx Pharmaceuticals secured approval in Canada on Monday for a new medicine to treat patients…
STAT+: Biotech is practically in San Diego’s DNA. Here’s how it got there — and how it might evolve
SAN DIEGO — More than 40 years ago, Ivor Royston, a brash young assistant professor…
STAT+: Simmering disputes persist as Covid patent waiver talks come down to the wire
On Sunday, the World Trade Organization will hold a long-delayed ministerial conference to craft a…
STAT+: Updated study results show a CRISPR treatment for blood diseases continues to benefit patients
Updated results announced Saturday from two clinical trials involving an experimental, genome-editing treatment showed prolonged…